STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	May. 31, 2015	May. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (624,525)	$ (840,888)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	171	171
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph. D.	555,263	730,619
Changes in operating assets and liabilities
Accounts payable	(18,370)	(5,900)
Accrued liabilities	8,878	(13,022)
NET CASH USED IN OPERATING ACTIVITIES	(78,583)	(129,020)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	76,783	130,675
NET CASH PROVIDED BY FINANCING ACTIVITIES	76,783	130,675
NET INCREASE (DECREASE) IN CASH	(1,800)	1,655
CASH AT BEGINNING OF PERIOD	2,280	229
CASH AT END OF PERIOD	$ 480	$ 1,884